 | • レポートコード：MRC2-11QY11289 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は去勢抵抗性前立腺がん治療のグローバル市場について調査・分析したレポートです。種類別（ホルモン療法、抗アンドロゲン追加、抗アンドロゲン中止、エストロゲン、化学療法、放射線療法、その他）市場規模、用途別（病院、外来手術センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別去勢抵抗性前立腺がん治療の競争状況、市場シェア ・世界の去勢抵抗性前立腺がん治療市場：種類別市場規模 2015年-2020年（ホルモン療法、抗アンドロゲン追加、抗アンドロゲン中止、エストロゲン、化学療法、放射線療法、その他） ・世界の去勢抵抗性前立腺がん治療市場：種類別市場規模予測 2021年-2026年（ホルモン療法、抗アンドロゲン追加、抗アンドロゲン中止、エストロゲン、化学療法、放射線療法、その他） ・世界の去勢抵抗性前立腺がん治療市場：用途別市場規模 2015年-2020年（病院、外来手術センター） ・世界の去勢抵抗性前立腺がん治療市場：用途別市場規模予測 2021年-2026年（病院、外来手術センター） ・北米の去勢抵抗性前立腺がん治療市場分析：米国、カナダ ・ヨーロッパの去勢抵抗性前立腺がん治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの去勢抵抗性前立腺がん治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の去勢抵抗性前立腺がん治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの去勢抵抗性前立腺がん治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Active Biotech、Diagnocure、Glaxosmithkline、Northwest Biotherapeutics、Millennium Pharmaceuticals、Hologic、Spectrum Pharmaceuticals、Abbott Laboratories、Bayer Healthcare Pharmaceuticals ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Prostate cancer can be defined as it is a form of cancer that develops into male reproductive system. Most of the prostate cancer are slow growing and stable but sometimes it can spread from prostate (gland) to other part of body such as bone and lymph node. Initially prostate cancer does not pose any symptom but in severe cases it can cause pain during urination and can cause problem during sexual intercourse. Castration resistant prostate cancer is referred to as a prostate cancer that is spread to other parts of body and is resistant to medical or surgical treatment. Risk factor for castration resistant prostate cancer includes genetic predisposition, geriatric population, unhygienic diet, medication exposure and many sexual partners. Diagnosis for the detection of castration resistant prostate cancer includes prostate imaging, biopsy, tumor marker and staging test. Crucial factor about castration resistant prostate cancer is that it is resistant to medical and surgical treatment. However, other treatment options that are available in the market include hormone therapy, immune modulation, antiangiogenic treatment and bone targeted therapies.
North America dominates the global market for castration resistant prostate cancer treatment due to presence of large prostate cancer population in this region. Moreover, increasing demand of diagnostic test, increasing awareness among people and initiative taken by the federal government also accounted for the market growth in North American region. Europe represents the second position in the global castration resistant prostate cancer treatment market due to presence of large geriatric population base in European region. Asia-Pacific is considered as an untapped market due to lack of awareness and lack of proper healthcare facilities in some Asian countries. Asian market growth will be fuelled by the presence of untapped opportunities due to extensive increase in the healthcare infrastructure (healthcare cost, healthcare facility and healthcare budget). Similarly, Asia-Pacific is considered as an emerging market during the study period due to growing market penetration in this region.
Market Analysis and Insights: Global Castration Resistant Prostate Cancer Treatment Market
The global Castration Resistant Prostate Cancer Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Castration Resistant Prostate Cancer Treatment Scope and Market Size
Castration Resistant Prostate Cancer Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Castration Resistant Prostate Cancer Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Active Biotech
Diagnocure
Glaxosmithkline
Northwest Biotherapeutics
Millennium Pharmaceuticals
Hologic
Spectrum Pharmaceuticals
Abbott Laboratories
Bayer Healthcare Pharmaceuticals
Market segment by Type, the product can be split into
Hormonal Therapy
Adding An Anti-Androgen
Stopping An Anti-Androgen
Estrogens
Chemotherapy
Radiation Therapy
Others
Market segment by Application, split into
Hospital
Ambulatory Surgical Centers
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Castration Resistant Prostate Cancer Treatment Revenue
1.4 Market by Type
1.4.1 Global Castration Resistant Prostate Cancer Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Hormonal Therapy
1.4.3 Adding An Anti-Androgen
1.4.4 Stopping An Anti-Androgen
1.4.5 Estrogens
1.4.6 Chemotherapy
1.4.7 Radiation Therapy
1.4.8 Others
1.5 Market by Application
1.5.1 Global Castration Resistant Prostate Cancer Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospital
1.5.3 Ambulatory Surgical Centers
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Castration Resistant Prostate Cancer Treatment Market Perspective (2015-2026)
2.2 Global Castration Resistant Prostate Cancer Treatment Growth Trends by Regions
2.2.1 Castration Resistant Prostate Cancer Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Castration Resistant Prostate Cancer Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Castration Resistant Prostate Cancer Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Castration Resistant Prostate Cancer Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Castration Resistant Prostate Cancer Treatment Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Castration Resistant Prostate Cancer Treatment Players by Market Size
3.1.1 Global Top Castration Resistant Prostate Cancer Treatment Players by Revenue (2015-2020)
3.1.2 Global Castration Resistant Prostate Cancer Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Castration Resistant Prostate Cancer Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Castration Resistant Prostate Cancer Treatment Market Concentration Ratio
3.2.1 Global Castration Resistant Prostate Cancer Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Castration Resistant Prostate Cancer Treatment Revenue in 2019
3.3 Castration Resistant Prostate Cancer Treatment Key Players Head office and Area Served
3.4 Key Players Castration Resistant Prostate Cancer Treatment Product Solution and Service
3.5 Date of Enter into Castration Resistant Prostate Cancer Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Castration Resistant Prostate Cancer Treatment Historic Market Size by Type (2015-2020)
4.2 Global Castration Resistant Prostate Cancer Treatment Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Castration Resistant Prostate Cancer Treatment Market Size by Application (2015-2020)
5.2 Global Castration Resistant Prostate Cancer Treatment Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Castration Resistant Prostate Cancer Treatment Market Size (2015-2020)
6.2 Castration Resistant Prostate Cancer Treatment Key Players in North America (2019-2020)
6.3 North America Castration Resistant Prostate Cancer Treatment Market Size by Type (2015-2020)
6.4 North America Castration Resistant Prostate Cancer Treatment Market Size by Application (2015-2020)
7 Europe
7.1 Europe Castration Resistant Prostate Cancer Treatment Market Size (2015-2020)
7.2 Castration Resistant Prostate Cancer Treatment Key Players in Europe (2019-2020)
7.3 Europe Castration Resistant Prostate Cancer Treatment Market Size by Type (2015-2020)
7.4 Europe Castration Resistant Prostate Cancer Treatment Market Size by Application (2015-2020)
8 China
8.1 China Castration Resistant Prostate Cancer Treatment Market Size (2015-2020)
8.2 Castration Resistant Prostate Cancer Treatment Key Players in China (2019-2020)
8.3 China Castration Resistant Prostate Cancer Treatment Market Size by Type (2015-2020)
8.4 China Castration Resistant Prostate Cancer Treatment Market Size by Application (2015-2020)
9 Japan
9.1 Japan Castration Resistant Prostate Cancer Treatment Market Size (2015-2020)
9.2 Castration Resistant Prostate Cancer Treatment Key Players in Japan (2019-2020)
9.3 Japan Castration Resistant Prostate Cancer Treatment Market Size by Type (2015-2020)
9.4 Japan Castration Resistant Prostate Cancer Treatment Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Castration Resistant Prostate Cancer Treatment Market Size (2015-2020)
10.2 Castration Resistant Prostate Cancer Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Castration Resistant Prostate Cancer Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Castration Resistant Prostate Cancer Treatment Market Size by Application (2015-2020)
11 India
11.1 India Castration Resistant Prostate Cancer Treatment Market Size (2015-2020)
11.2 Castration Resistant Prostate Cancer Treatment Key Players in India (2019-2020)
11.3 India Castration Resistant Prostate Cancer Treatment Market Size by Type (2015-2020)
11.4 India Castration Resistant Prostate Cancer Treatment Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Castration Resistant Prostate Cancer Treatment Market Size (2015-2020)
12.2 Castration Resistant Prostate Cancer Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Castration Resistant Prostate Cancer Treatment Market Size by Type (2015-2020)
12.4 Central & South America Castration Resistant Prostate Cancer Treatment Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Active Biotech
13.1.1 Active Biotech Company Details
13.1.2 Active Biotech Business Overview
13.1.3 Active Biotech Castration Resistant Prostate Cancer Treatment Introduction
13.1.4 Active Biotech Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020))
13.1.5 Active Biotech Recent Development
13.2 Diagnocure
13.2.1 Diagnocure Company Details
13.2.2 Diagnocure Business Overview
13.2.3 Diagnocure Castration Resistant Prostate Cancer Treatment Introduction
13.2.4 Diagnocure Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
13.2.5 Diagnocure Recent Development
13.3 Glaxosmithkline
13.3.1 Glaxosmithkline Company Details
13.3.2 Glaxosmithkline Business Overview
13.3.3 Glaxosmithkline Castration Resistant Prostate Cancer Treatment Introduction
13.3.4 Glaxosmithkline Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
13.3.5 Glaxosmithkline Recent Development
13.4 Northwest Biotherapeutics
13.4.1 Northwest Biotherapeutics Company Details
13.4.2 Northwest Biotherapeutics Business Overview
13.4.3 Northwest Biotherapeutics Castration Resistant Prostate Cancer Treatment Introduction
13.4.4 Northwest Biotherapeutics Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
13.4.5 Northwest Biotherapeutics Recent Development
13.5 Millennium Pharmaceuticals
13.5.1 Millennium Pharmaceuticals Company Details
13.5.2 Millennium Pharmaceuticals Business Overview
13.5.3 Millennium Pharmaceuticals Castration Resistant Prostate Cancer Treatment Introduction
13.5.4 Millennium Pharmaceuticals Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
13.5.5 Millennium Pharmaceuticals Recent Development
13.6 Hologic
13.6.1 Hologic Company Details
13.6.2 Hologic Business Overview
13.6.3 Hologic Castration Resistant Prostate Cancer Treatment Introduction
13.6.4 Hologic Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
13.6.5 Hologic Recent Development
13.7 Spectrum Pharmaceuticals
13.7.1 Spectrum Pharmaceuticals Company Details
13.7.2 Spectrum Pharmaceuticals Business Overview
13.7.3 Spectrum Pharmaceuticals Castration Resistant Prostate Cancer Treatment Introduction
13.7.4 Spectrum Pharmaceuticals Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
13.7.5 Spectrum Pharmaceuticals Recent Development
13.8 Abbott Laboratories
13.8.1 Abbott Laboratories Company Details
13.8.2 Abbott Laboratories Business Overview
13.8.3 Abbott Laboratories Castration Resistant Prostate Cancer Treatment Introduction
13.8.4 Abbott Laboratories Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
13.8.5 Abbott Laboratories Recent Development
13.9 Bayer Healthcare Pharmaceuticals
13.9.1 Bayer Healthcare Pharmaceuticals Company Details
13.9.2 Bayer Healthcare Pharmaceuticals Business Overview
13.9.3 Bayer Healthcare Pharmaceuticals Castration Resistant Prostate Cancer Treatment Introduction
13.9.4 Bayer Healthcare Pharmaceuticals Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
13.9.5 Bayer Healthcare Pharmaceuticals Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Castration Resistant Prostate Cancer Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Castration Resistant Prostate Cancer Treatment Revenue
Table 3. Ranking of Global Top Castration Resistant Prostate Cancer Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Castration Resistant Prostate Cancer Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Hormonal Therapy
Table 6. Key Players of Adding An Anti-Androgen
Table 7. Key Players of Stopping An Anti-Androgen
Table 8. Key Players of Estrogens
Table 9. Key Players of Chemotherapy
Table 10. Key Players of Radiation Therapy
Table 11. Key Players of Others
Table 12. Global Castration Resistant Prostate Cancer Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 13. Global Castration Resistant Prostate Cancer Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 14. Global Castration Resistant Prostate Cancer Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 15. Global Castration Resistant Prostate Cancer Treatment Market Share by Regions (2015-2020)
Table 16. Global Castration Resistant Prostate Cancer Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 17. Global Castration Resistant Prostate Cancer Treatment Market Share by Regions (2021-2026)
Table 18. Market Top Trends
Table 19. Key Drivers: Impact Analysis
Table 20. Key Challenges
Table 21. Castration Resistant Prostate Cancer Treatment Market Growth Strategy
Table 22. Main Points Interviewed from Key Castration Resistant Prostate Cancer Treatment Players
Table 23. Global Castration Resistant Prostate Cancer Treatment Revenue by Players (2015-2020) (Million US$)
Table 24. Global Castration Resistant Prostate Cancer Treatment Market Share by Players (2015-2020)
Table 25. Global Top Castration Resistant Prostate Cancer Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Castration Resistant Prostate Cancer Treatment as of 2019)
Table 26. Global Castration Resistant Prostate Cancer Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 27. Key Players Headquarters and Area Served
Table 28. Key Players Castration Resistant Prostate Cancer Treatment Product Solution and Service
Table 29. Date of Enter into Castration Resistant Prostate Cancer Treatment Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Castration Resistant Prostate Cancer Treatment Market Size by Type (2015-2020) (Million US$)
Table 32. Global Castration Resistant Prostate Cancer Treatment Market Size Share by Type (2015-2020)
Table 33. Global Castration Resistant Prostate Cancer Treatment Revenue Market Share by Type (2021-2026)
Table 34. Global Castration Resistant Prostate Cancer Treatment Market Size Share by Application (2015-2020)
Table 35. Global Castration Resistant Prostate Cancer Treatment Market Size by Application (2015-2020) (Million US$)
Table 36. Global Castration Resistant Prostate Cancer Treatment Market Size Share by Application (2021-2026)
Table 37. North America Key Players Castration Resistant Prostate Cancer Treatment Revenue (2019-2020) (Million US$)
Table 38. North America Key Players Castration Resistant Prostate Cancer Treatment Market Share (2019-2020)
Table 39. North America Castration Resistant Prostate Cancer Treatment Market Size by Type (2015-2020) (Million US$)
Table 40. North America Castration Resistant Prostate Cancer Treatment Market Share by Type (2015-2020)
Table 41. North America Castration Resistant Prostate Cancer Treatment Market Size by Application (2015-2020) (Million US$)
Table 42. North America Castration Resistant Prostate Cancer Treatment Market Share by Application (2015-2020)
Table 43. Europe Key Players Castration Resistant Prostate Cancer Treatment Revenue (2019-2020) (Million US$)
Table 44. Europe Key Players Castration Resistant Prostate Cancer Treatment Market Share (2019-2020)
Table 45. Europe Castration Resistant Prostate Cancer Treatment Market Size by Type (2015-2020) (Million US$)
Table 46. Europe Castration Resistant Prostate Cancer Treatment Market Share by Type (2015-2020)
Table 47. Europe Castration Resistant Prostate Cancer Treatment Market Size by Application (2015-2020) (Million US$)
Table 48. Europe Castration Resistant Prostate Cancer Treatment Market Share by Application (2015-2020)
Table 49. China Key Players Castration Resistant Prostate Cancer Treatment Revenue (2019-2020) (Million US$)
Table 50. China Key Players Castration Resistant Prostate Cancer Treatment Market Share (2019-2020)
Table 51. China Castration Resistant Prostate Cancer Treatment Market Size by Type (2015-2020) (Million US$)
Table 52. China Castration Resistant Prostate Cancer Treatment Market Share by Type (2015-2020)
Table 53. China Castration Resistant Prostate Cancer Treatment Market Size by Application (2015-2020) (Million US$)
Table 54. China Castration Resistant Prostate Cancer Treatment Market Share by Application (2015-2020)
Table 55. Japan Key Players Castration Resistant Prostate Cancer Treatment Revenue (2019-2020) (Million US$)
Table 56. Japan Key Players Castration Resistant Prostate Cancer Treatment Market Share (2019-2020)
Table 57. Japan Castration Resistant Prostate Cancer Treatment Market Size by Type (2015-2020) (Million US$)
Table 58. Japan Castration Resistant Prostate Cancer Treatment Market Share by Type (2015-2020)
Table 59. Japan Castration Resistant Prostate Cancer Treatment Market Size by Application (2015-2020) (Million US$)
Table 60. Japan Castration Resistant Prostate Cancer Treatment Market Share by Application (2015-2020)
Table 61. Southeast Asia Key Players Castration Resistant Prostate Cancer Treatment Revenue (2019-2020) (Million US$)
Table 62. Southeast Asia Key Players Castration Resistant Prostate Cancer Treatment Market Share (2019-2020)
Table 63. Southeast Asia Castration Resistant Prostate Cancer Treatment Market Size by Type (2015-2020) (Million US$)
Table 64. Southeast Asia Castration Resistant Prostate Cancer Treatment Market Share by Type (2015-2020)
Table 65. Southeast Asia Castration Resistant Prostate Cancer Treatment Market Size by Application (2015-2020) (Million US$)
Table 66. Southeast Asia Castration Resistant Prostate Cancer Treatment Market Share by Application (2015-2020)
Table 67. India Key Players Castration Resistant Prostate Cancer Treatment Revenue (2019-2020) (Million US$)
Table 68. India Key Players Castration Resistant Prostate Cancer Treatment Market Share (2019-2020)
Table 69. India Castration Resistant Prostate Cancer Treatment Market Size by Type (2015-2020) (Million US$)
Table 70. India Castration Resistant Prostate Cancer Treatment Market Share by Type (2015-2020)
Table 71. India Castration Resistant Prostate Cancer Treatment Market Size by Application (2015-2020) (Million US$)
Table 72. India Castration Resistant Prostate Cancer Treatment Market Share by Application (2015-2020)
Table 73. Central & South America Key Players Castration Resistant Prostate Cancer Treatment Revenue (2019-2020) (Million US$)
Table 74. Central & South America Key Players Castration Resistant Prostate Cancer Treatment Market Share (2019-2020)
Table 75. Central & South America Castration Resistant Prostate Cancer Treatment Market Size by Type (2015-2020) (Million US$)
Table 76. Central & South America Castration Resistant Prostate Cancer Treatment Market Share by Type (2015-2020)
Table 77. Central & South America Castration Resistant Prostate Cancer Treatment Market Size by Application (2015-2020) (Million US$)
Table 78. Central & South America Castration Resistant Prostate Cancer Treatment Market Share by Application (2015-2020)
Table 79. Active Biotech Company Details
Table 80. Active Biotech Business Overview
Table 81. Active Biotech Product
Table 82. Active Biotech Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020) (Million US$)
Table 83. Active Biotech Recent Development
Table 84. Diagnocure Company Details
Table 85. Diagnocure Business Overview
Table 86. Diagnocure Product
Table 87. Diagnocure Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020) (Million US$)
Table 88. Diagnocure Recent Development
Table 89. Glaxosmithkline Company Details
Table 90. Glaxosmithkline Business Overview
Table 91. Glaxosmithkline Product
Table 92. Glaxosmithkline Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020) (Million US$)
Table 93. Glaxosmithkline Recent Development
Table 94. Northwest Biotherapeutics Company Details
Table 95. Northwest Biotherapeutics Business Overview
Table 96. Northwest Biotherapeutics Product
Table 97. Northwest Biotherapeutics Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020) (Million US$)
Table 98. Northwest Biotherapeutics Recent Development
Table 99. Millennium Pharmaceuticals Company Details
Table 100. Millennium Pharmaceuticals Business Overview
Table 101. Millennium Pharmaceuticals Product
Table 102. Millennium Pharmaceuticals Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020) (Million US$)
Table 103. Millennium Pharmaceuticals Recent Development
Table 104. Hologic Company Details
Table 105. Hologic Business Overview
Table 106. Hologic Product
Table 107. Hologic Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020) (Million US$)
Table 108. Hologic Recent Development
Table 109. Spectrum Pharmaceuticals Company Details
Table 110. Spectrum Pharmaceuticals Business Overview
Table 111. Spectrum Pharmaceuticals Product
Table 112. Spectrum Pharmaceuticals Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020) (Million US$)
Table 113. Spectrum Pharmaceuticals Recent Development
Table 114. Abbott Laboratories Business Overview
Table 115. Abbott Laboratories Product
Table 116. Abbott Laboratories Company Details
Table 117. Abbott Laboratories Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020) (Million US$)
Table 118. Abbott Laboratories Recent Development
Table 119. Bayer Healthcare Pharmaceuticals Company Details
Table 120. Bayer Healthcare Pharmaceuticals Business Overview
Table 121. Bayer Healthcare Pharmaceuticals Product
Table 122. Bayer Healthcare Pharmaceuticals Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020) (Million US$)
Table 123. Bayer Healthcare Pharmaceuticals Recent Development
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Castration Resistant Prostate Cancer Treatment Market Share by Type: 2020 VS 2026
Figure 2. Hormonal Therapy Features
Figure 3. Adding An Anti-Androgen Features
Figure 4. Stopping An Anti-Androgen Features
Figure 5. Estrogens Features
Figure 6. Chemotherapy Features
Figure 7. Radiation Therapy Features
Figure 8. Others Features
Figure 9. Global Castration Resistant Prostate Cancer Treatment Market Share by Application: 2020 VS 2026
Figure 10. Hospital Case Studies
Figure 11. Ambulatory Surgical Centers Case Studies
Figure 12. Castration Resistant Prostate Cancer Treatment Report Years Considered
Figure 13. Global Castration Resistant Prostate Cancer Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 14. Global Castration Resistant Prostate Cancer Treatment Market Share by Regions: 2020 VS 2026
Figure 15. Global Castration Resistant Prostate Cancer Treatment Market Share by Regions (2021-2026)
Figure 16. Porter's Five Forces Analysis
Figure 17. Global Castration Resistant Prostate Cancer Treatment Market Share by Players in 2019
Figure 18. Global Top Castration Resistant Prostate Cancer Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Castration Resistant Prostate Cancer Treatment as of 2019
Figure 19. The Top 10 and 5 Players Market Share by Castration Resistant Prostate Cancer Treatment Revenue in 2019
Figure 20. North America Castration Resistant Prostate Cancer Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Europe Castration Resistant Prostate Cancer Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. China Castration Resistant Prostate Cancer Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Japan Castration Resistant Prostate Cancer Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Southeast Asia Castration Resistant Prostate Cancer Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. India Castration Resistant Prostate Cancer Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Central & South America Castration Resistant Prostate Cancer Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Bottom-up and Top-down Approaches for This Report
Figure 28. Data Triangulation
Figure 29. Key Executives Interviewed
前立腺がん治療の世界市場（～2026年） Prostate cancer is the most common cancer among men, the key risk factors for prostate cancer development is being old age, genetic, obesity and race. Market Analysis and Insights: Global Prostate Cancer Treatment Market The global Prostate Cancer Treatment market size is projected to reach US$ XX m…- ホルモン抵抗性前立腺がんの世界市場（～2026年） Hormone Refractory Prostate Cancer (HRPCA) or Castrate-Resistant Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after having hormonal therapy, is now under the spotlight in prostate cancer market. Due to the high unmet clinical need associated with limited survival periods, …
- 前立腺がんの世界市場（～2026年） Prostate cancer is cancer that occurs in the prostate. Market Analysis and Insights: Global Prostate Cancer Market The global Prostate Cancer market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Prostate Cancer Scope and Ma…
- 前立腺がん診断・治療の世界市場（～2026年） Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. The market is growing impressively due to rise in incidence and prevalence rate of prostate cancer, robust R&D exploration and rising investment in grants and investment across the globe. Market An…
- 前立腺がん治療薬の世界市場（～2026年） Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. This cancer develops slowly, with no early detectable symptoms for many years. The precise cause of prostate cancer is unknown; however, factors such as obesity, high calcium diet, lack of exercise…